Dossier assessment
Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Report documents
-
Extract of dossier assessment
Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
-
Dossier assessment
Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Dossier assessment
Patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer after prior endocrine therapy
PALOMA-3 study unsuitable for the derivation of an added benefit due to inadequate implementation of appropriate comparator therapy; added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.
Project details
- Project no.
- A18-63
- Commission
- Commission awarded on 01.08.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Palbociclib (breast cancer) – Benefit assessment according to § 35a SGB V
Status: Commission completed